<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749994</url>
  </required_header>
  <id_info>
    <org_study_id>ID-ROEZ-302</org_study_id>
    <nct_id>NCT02749994</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)</brief_title>
  <acronym>I-ROSETTE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase Ⅲ, multi-center, randomized, double-blinded, active comparator, factorial design
      clinical trial to compare the efficacy and safety of a combination therapy of ezetimibe and
      rosuvastatin versus monotherapy of rosuvastatin in hypercholesterolemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline to 8 week in LDL-Cholesterol</measure>
    <time_frame>baseline and 8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in Total Cholesterol</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in Triglyceride</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in HDL-Cholesterol</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in Apolipoprotein B</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in Apolipoprotein A1</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 week in LDL-Cholesterol</measure>
    <time_frame>baseline to 4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)</measure>
    <time_frame>baseline to 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of LDL-Cholesterol/HDL-Cholesterol ratio</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Total Cholesterol/HDL-Cholesterol ratio</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of non-HDL-Cholesterol/HDL-Cholesterol ratio</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Apolipoprotein B/Apolipoprotein A1 ratio</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline</measure>
    <time_frame>baseline to 4 and 8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>R5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R5/E10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 5mg/Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R10/E10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10mg/Ezetimibe 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R20/E10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg/Ezetimibe 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>R5</arm_group_label>
    <arm_group_label>R10</arm_group_label>
    <arm_group_label>R20</arm_group_label>
    <arm_group_label>R5/E10</arm_group_label>
    <arm_group_label>R10/E10</arm_group_label>
    <arm_group_label>R20/E10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <arm_group_label>R5/E10</arm_group_label>
    <arm_group_label>R10/E10</arm_group_label>
    <arm_group_label>R20/E10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 ~ 79 years old

          2. Patients who confirmed hypercholesterolemia.

          3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol
             Education Program Adult Treatment Panel) III Guideline at Visit2.

          4. Patients with Triglyceride&lt; 400 at Visit 2.

          5. Patients who have a wash-out period over 4 weeks for other drugs that can affect lipid
             profile.(Patients who have lipid regulators should have washout period over six weeks)

          6. Patients who agreed to participate in the trial

        Exclusion Criteria:

          1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or
             hypersensitivity to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase
             inhibitors) or ezetimibe.

          2. A heavy alcohol consumer. (alcohol &gt; 25 units/week)

          3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)

          4. Patients with active liver disease and AST(aspartate transaminase) or ALT(alanine
             transaminase) &gt; 2 times of upper limit of normal range.

          5. Patients with CPK(creatine phosphokinase) &gt; 2 x upper limit of normal range.

          6. Patients who have a endocrine or metabolic diseases known to affect the serum
             phospholipid or lipoprotein.

          7. Patients with HIV(human immunodeficiency virus positive.

          8. Patients who have a acute arteriopathy.

          9. Patients with uncontrolled hypertension.

         10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption.

         11. Patients who have a drugs absorption disorder by gastrointestinal surgery or
             gastrointestinal disorder.

         12. Patients with tumor.

         13. Patients who have hormonal therapy.

         14. Pregnancy or breastfeeding patients who don't agree to use adequate contraception.

         15. Patients who are judged unsuitable to participate in this study by investigator.

         16. Patients taking other clinical trial drugs within 30 days from the time of visit for
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-soo Kim, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>March 12, 2017</last_update_submitted>
  <last_update_submitted_qc>March 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

